1 tracked superinvestor hold BRIDGEBIO PHARMA INC (BBIO), worth $741M combined, led by Andreas Halvorsen. Smart money is trimming BBIO as of the latest 13F filings.
Current price
$74.84
+44.4%
1Y
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10…
Market cap
$13.3B
P/E
-18.14
Div yield
0.0%
Revenue YoY
126.3%
Analyst target
$109
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$741M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
-1
0 buying · 1 selling
Smart money is net reducing BBIO: 1 funds trimmed versus 0 adding.
BRIDGEBIO PHARMA INC (BBIO) is held by 1 tracked funds worth $741M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Andreas Halvorsen at 2.1% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
No tracked fund opened a new position this quarter; 0 added and 1 trimmed, a net reduction.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Trimmed | 2.1% | $741M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
3 insiders filed SEC Form 144 for $7M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Kumar Haldea Family Irrevocable Tru/T/A Dtd 05/18/2019 | Director & Officer | 30,000 | $2M | 2026-08-19 |
| Neil Kumar | Director & Officer | 34,980 | $3M | 2026-08-18 |
| Randal Scott | Director | 21,501 | $2M | 2026-08-17 |
Which superinvestors own BBIO?
1 tracked funds hold BRIDGEBIO PHARMA INC (BBIO), the largest being Andreas Halvorsen (Viking Global Investors) at 2.1% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling BBIO?
In the most recent 13F quarter, 0 tracked funds added or opened BBIO and 1 trimmed it.
How much BBIO do tracked funds hold?
Combined disclosed long exposure to BBIO across tracked superinvestors is $741M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.